Palvella Reports Positive Phase 3 Data for QTORIN

Palvella Therapeutics ( (PVLA) ) just unveiled an update.

On May 20, 2026, Palvella Therapeutics reported new positive Phase 3 SELVA and Phase 2 TOIVA clinical data for its topical QTORIN rapamycin gel at the International Society for the Study of Vascular Anomalies World Congress 2026 in Philadelphia, underscoring its ambition to establish the drug as a first-in-disease therapy for serious rare vascular malformations. In children aged 6–11 years with microcystic lymphatic malformations in SELVA, all 13 participants were rated “Much Improved” or “Very Much Improved” on the mLM-IGA at Week 24, while 87% of those with moderate or worse leaking or bleeding at baseline showed similar improvement, and all 43 evaluable patients reported at least some satisfaction with treatment.

Blinded independent review in SELVA showed stable disease during an eight-week pre-treatment run-in followed by marked improvement over 24 weeks of QTORIN rapamycin, supporting the trial’s single-arm, baseline-controlled design. In the TOIVA Phase 2 trial in cutaneous venous malformations, QTORIN rapamycin produced statistically significant reductions in lesion height and appearance scores at all measured time points, with greater clinical response seen by Week 24.

Palvella highlighted that QTORIN rapamycin has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for microcystic lymphatic malformations, along with Fast Track status for cutaneous venous malformations, reinforcing regulatory support in these high-need indications. The company stated it remains on track to submit a New Drug Application for microcystic lymphatic malformations in the second half of 2026 and to initiate a Phase 3 trial in cutaneous venous malformations in the same timeframe, moves that could significantly advance its competitive position in rare dermatologic and vascular disease markets if subsequent regulatory and clinical milestones are achieved.

The most recent analyst rating on (PVLA) stock is a Buy with a $227.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

The score is held back primarily by weak financial performance (no current revenue, widening losses, and sustained cash burn), partially offset by a strong balance-sheet leverage profile. Technicals are mixed with neutral momentum, while valuation is constrained by loss-making metrics and no dividend support. Positive corporate events—especially clinical progress and regulatory/financing milestones—provide meaningful upside support but do not fully offset the current fundamentals.

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations that currently lack U.S. Food and Drug Administration-approved treatments. The company’s pipeline is built on its patented QTORIN platform, led by QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas, and QTORIN pitavastatin for disseminated superficial actinic porokeratosis.

Founded and led by rare disease biotech veterans, Palvella is targeting lifelong, localized cutaneous conditions with topical therapies designed to address underlying disease biology while minimizing systemic exposure. The company trades on Nasdaq under the ticker PVLA and is positioning QTORIN-based candidates as potential first-in-disease standards of care in multiple underserved rare dermatologic and vascular indications.

Average Trading Volume: 297,527

Technical Sentiment Signal: Buy

Current Market Cap: $1.51B

For detailed information about PVLA stock, go to TipRanks’ Stock Analysis page.